Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension.
1. The aim of the present study was to determine the effect of hypotensive therapy with a diuretic (hydrochlorothiazide) and an angiotensin-converting enzyme inhibitor (perindopril) on selected oxidative stress parameters in the blood of elderly patients with essential hypertension. 2. Studies were performed in 45 elderly patients with essential hypertension at baseline and after the 45th day of perindopril (n = 25) or hydrochlorothiazide (n = 20) therapy, as well as in 25 young and 25 elderly normotensive subjects. The following parameters were measured: systolic and diastolic blood pressure, nitric oxide (NO), carbonyl groups and malondialdehyde (MDA) concentrations, as well as the activity of ceruloplasmin (Cp) oxidase, Cu-Zn superoxide dismutase (SOD-1) and catalase (CAT). 3. The activity of SOD-1 and NO levels were reduced with age. 4. Compared with elderly controls, hypertensive subjects showed increases in baseline MDA, carbonyl group concentrations and Cp oxidase activity and decreases in NO levels and SOD-1 and CAT activities. 5. Treatment with perindopril, but not hydrochlorothiazide, resulted in significant increases in SOD-1 and CAT activities and decreases in MDA concentration and Cp oxidase activity. Both therapies decreased the level of carbonyl groups and increased NO levels. 6. Angiotensin-converting enzyme inhibitor therapy has significant anti-oxidant effects that may be important in the treatment of elderly patients with essential hypertension.
Kedziora-Kornatowska
Kornelia
K
Department and Clinic of Geriatrics, Bydgoszcz Medical College, N Copernicus University, Bydgoszcz, Poland.
Czuczejko
Jolanta
J
Szewczyk-Golec
Karolina
K
Motyl
Jadwiga
J
Szadujkis-Szadurski
Leszek
L
Kornatowski
Tomasz
T
Pawluk
Hanna
H
Kedziora
Józef
J
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D002374:Catalase / Q000097:blood; D004232:Diuretics / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects*; D020913:Perindopril / Q000494:pharmacology* / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000097:blood; D000072105:Superoxide Dismutase-1
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D009566:Nitrates; D009573:Nitrites; C000606290:SOD1 protein, human; D006852:Hydrochlorothiazide; D008315:Malondialdehyde; D002374:Catalase; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D020913:Perindopril